Pasar al contenido principal

ABORDAJE MEDIANTE TECNICAS OMICAS DE LA MODULACION DE LAS CELULAS HOSPEDADORAS POR LEISHMANIA: SU IMPLICACION EN LA SENSIBILIDAD A FARMACOS.

RTI2018-097210-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Synthesis and Biophysical and Biological Studies of N-Phenylbenzamide Derivatives Targeting Kinetoplastid Parasites

  • Nué-Martinez, J.J.
  • Cisneros, David
  • Moreno-Blázquez, María del Valle
  • Fonseca-Berzal, Cristina
  • Manzano, J.I
  • Kraeutler, D
  • Ungogo, M.A
  • Aloraini, M.A
  • Elati, H.A.A
  • Ibáñez Escribano, Alexandra
  • Lagartera, L
  • Herraiz, Tomás
  • Gamarro, Francisco
  • de Koning, Harry P
  • Gómez-Barrio, Alicia
  • Dardonville, Christophe
The AT-rich mitochondrial DNA (kDNA) of trypanosomatid parasites is a target of DNA minor groove binders. We report the synthesis, antiprotozoal screening, and SAR studies of three series of analogues of the known antiprotozoal kDNA binder 2-((4-(4-((4,5-dihydro-1H-imidazol-3-ium-2-yl)amino)benzamido)phenyl)amino)-4,5-dihydro-1H-imidazol-3-ium (1a). Bis(2-aminoimidazolines) (1) and bis(2-aminobenzimidazoles) (2) showed micromolar range activity against Trypanosoma brucei, whereas bisarylimidamides (3) were submicromolar inhibitors of T. brucei, Trypanosoma cruzi, and Leishmania donovani. None of the compounds showed relevant activity against the urogenital, nonkinetoplastid parasite Trichomonas vaginalis. We show that series 1 and 3 bind strongly and selectively to the minor groove of AT DNA, whereas series 2 also binds by intercalation. The measured pKa indicated different ionization states at pH 7.4, which correlated with the DNA binding affinities (ΔTm) for series 2 and 3. Compound 3a, which was active and selective against the three parasites and displayed adequate metabolic stability, is a fine candidate for in vivo studies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thiol-ene "click" synthesis and pharmacological evaluation of c-glycoside sp2-iminosugar glycolipids

  • Sánchez-Fernández, Elena M.
  • García-Moreno, M. Isabel
  • García-Hernández, Raquel
  • Padrón, José M.
  • García Fernández, José Manuel
  • Gamarro, Francisco
  • Ortiz Mellet, Carmen
The unique stereoelectronic properties of sp2-iminosugars enable their participation in glycosylation reactions, thereby behaving as true carbohydrate chemical mimics. Among sp2-iminosugar conjugates, the sp2-iminosugar glycolipids (sp2-IGLs) have shown a variety of interesting pharmacological properties ranging from glycosidase inhibition to antiproliferative, antiparasitic, and anti-inflammatory activities. Developing strategies compatible with molecular diversity-oriented strategies for structure–activity relationship studies was therefore highly wanted. Here we show that a reaction sequence consisting in stereoselective C-allylation followed by thiol-ene “click” coupling provides a very convenient access to α-C-glycoside sp2-IGLs. Both the glycone moiety and the aglycone tail can be modified by using sp2-iminosugar precursors with different configurational profiles (d-gluco or d-galacto in this work) and varied thiols, as well as by oxidation of the sulfide adducts (to the corresponding sulfones in this work). A series of derivatives was prepared in this manner and their glycosidase inhibitory, antiproliferative and antileishmanial activities were evaluated in different settings. The results confirm that the inhibition of glycosidases, particularly α-glucosidase, and the antitumor/leishmanicidal activities are unrelated. The data are also consistent with the two later activities arising from the ability of the sp2-IGLs to interfere in the immune system response in a cell line and cell context dependent manner., This study was supported by the Spanish Ministerio de Economía y Competitividad (contract numbers RTI2018-093940-B-I00 and SAF2016-76083-R), the Spanish Ministerio de Ciencia, Innovación y Universidades (RTI2018-097210-B-I00 to FG), the European Regional Development Funds (FEDER and FSE). J.M.P. thanks the Spanish Government for financial support through project PGC2018-094503-B-C22 (MCIU/AEI/FEDER, UE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

4-Aminoquinoline-based compounds as antileishmanial agents that inhibit the energy metabolism of Leishmania

  • Manzano, José Ignacio
  • Konstantinovi, J.
  • Scaccabarozzi, D.
  • Perea, A.
  • Pavi, A.
  • Cavicchini, L.
  • Basilico, N.
  • Gamarro, Francisco
  • Šolaja, B.A.
Among neglected tropical diseases, leishmaniasis is one of the most relevant with an estimated 30,000 deaths annually. Existing therapies have serious drawbacks in safety, drug resistance, field-adapted application and cost; therefore, new safer and shorter treatments are needed for this disease. Here we report on the synthesis of novel 4-amino-7-chloroquinoline-based compounds with leishmanicidal activity, together with deeper insight into the mechanism of action of our previously published hit compound 1. New derivatives showed comparable activity to 1 against both promastigote and intracellular amastigote forms of Leishmania infantum, with IC < 1 μM. Furthermore, we have determined that compound 1 induced a decrease of intracellular ATP levels, as well as a mitochondrial depolarization, together with an alteration of plasma membrane permeability and a significant ROS production. The inhibition of the energy metabolism of Leishmania plays an important role in the leishmanicidal mechanism of this compound. In all, these results support the consideration of compound 1 for the future development of new leishmanicidal drugs., This work was supported by the Ministry of Education, Science and Technological Development of Serbia Grant #172008 (JK, BS), Grant #173048 (AP), Serbian Academy of Sciences and Arts (BS, Grant #F80), Ministero dell’Istruzione, dell’Università e della Ricerca [PRIN 2015.4JRJPP_004] and University of Milan “Piano sostegno alla Ricerca, Linea 2 2018”, (NB) and the Spanish Ministerio de Ciencia, Innovación y Universidades Grant (RTI2018-097210-B-I00 to FG).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis of polyfluoroalkyl sp2-iminosugar glycolipids and evaluation of their immunomodulatory properties towards anti-tumor, anti-leishmanial and anti-inflammatory therapies

  • Sánchez-Fernández, Elena M.
  • García-Moreno, M. Isabel
  • Arroba, Ana I.
  • Aguilar-Diosdado, Manuel
  • Padrón, José M.
  • García-Hernández, Raquel
  • Gamarro, Francisco
  • Fustero, Santos
  • Sánchez-Aparicio, José-Emilio
  • Masgrau, Laura
  • García Fernández, José Manuel
  • Ortiz Mellet, Carmen
Immunomodulatory glycolipids, among which α-galactosylceramide (KRN7000) is an iconic example, have shown strong therapeutic potential in a variety of conditions ranging from cancer and infection to autoimmune or neurodegenerative diseases. A main difficulty for those channels is that they often provoke a cytokine storm comprising both pro- and anti-inflammatory mediators that antagonize each other and negatively affect the immune response. The synthesis of analogues with narrower cytokine secretion-inducing capabilities is hampered by the intrinsic difficulty at controlling the stereochemical outcome in glycosidation reactions, particularly if targeting the α-anomer, which seriously hampers drug optimization strategies. Here we show that replacing the monosaccharide glycone by a sp-iminosugar glycomimetic moiety allows accessing N-linked sp-iminosugar glycolipids (sp-IGLs) with total α-stereocontrol in a single step with no need of protecting groups or glycosidation promotors. The lipid tail has been then readily tailored by incorporating polyfluoroalkyl segments of varied lengths in view of favouring binding to the lipid binding site of the master p38 mitogen activated protein kinase (p38 MAPK), thereby polarizing the immune response in a cell-context dependent manner. The compounds have been evaluated for their antiproliferative, anti-leishmanial and anti-inflammatory activities in different cell assays. The size of the fluorous segment was found to be critical for the biological activity, probably by regulating the aggregation and membrane-crossing properties, whereas the hydroxylation profile (gluco or galacto-like) was less relevant. Biochemical and computational data further support a mechanism of action implying binding to the allosteric lipid binding site of p38 MAPK and subsequent activation of the noncanonical autophosphorylation route. The ensemble of results provide a proof of concept of the potential of sp-IGLs as immunoregulators., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness/Ministry of Science, Education and Universities: SAF2016-76083-R (MINECO-FEDER), RTI2018-097210-B-I00 (MINCIU-FEDER) to FG, CTQ2015-64425-C2-1-R (MINECO-FEDER) and RTI2018-097609-B-C21 (MINCIU-FEDER). JMP thanks the Spanish Government for financial support through project PGC2018-094503-B-C22 (MINCIU-/AEI/FEDER, UE). Technical assistance from the research support services of the University of Seville (CITIUS) is also acknowledged. A.I.A. supported this work by grants from Instituto de Salud Carlos III (PI18/01287) and Consejería de Salud de la Junta de Andalucía (PI-0123-2018). MAD supported this work by grants from Convocatoria de subvenciones para la financiación de la investigación y la innovación biomédica y en Ciencias de la Salud en el marco de la iniciativa territorial integrada 2014–2020 para la provincia de Cádiz, Fondos ITI-FEDER (PI-0029-2017) and from Instituto de Salud Carlos III (PI18/01287).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery and pharmacological studies of 4-hydroxyphenyl-derived phosphonium salts active in a mouse model of visceral Leishmaniasis

  • Manzano, José Ignacio
  • Cueto-Díaz, Eduardo J.
  • Olías-Molero, Ana Isabel
  • Perea Martínez, Ana
  • Herraiz Tomico, Tomás
  • Torrado, Juan J.
  • Alunda, José María
  • Gamarro, Francisco
  • Dardonville, Christophe
We report the discovery of new 4-hydroxyphenyl phosphonium salt derivatives active in the submicromolar range (EC from 0.04 to 0.28 μM, SI > 10) against the protozoan parasite Leishmania donovani. The pharmacokinetics and in vivo oral efficacy of compound 1 [(16-(2,4-dihydroxyphenyl)-16-oxohexadecyl)triphenylphosphonium bromide] in a mouse model of visceral leishmaniasis were established. Compound 1 reduced the parasite load in spleen (98.9%) and liver (95.3%) of infected mice after an oral dosage of four daily doses of 1.5 mg/kg. Mode of action studies showed that compound 1 diffuses across the plasma membrane, as designed, and targets the mitochondrion of Leishmania parasites. Disruption of the energetic metabolism, with a decrease of intracellular ATP levels as well as mitochondrial depolarization together with a significant reactive oxygen species production, contributes to the leishmanicidal effect of 1. Importantly, this compound was equally effective against antimonials and miltefosine-resistant clinical isolates of Leishmania infantum, indicating its potential as antileishmanial lead., Funding from the Spanish Ministerio de Economia y Competitividad (grant SAF2015-66690-R) and the Spanish Ministerio de Ciencia, Innovacion y Universidades (MCIU/AEI/FEDER, UE; grants RTI2018-093940-B-I00 to C.D. and RTI2018-097210-B-I00 to F.G.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and biophysical and biological studies of N-phenylbenzamide derivatives targeting kinetoplastid parasites

  • Nué Martínez, J. Jonathan
  • Cisneros, David
  • Moreno-Blázquez, María del Valle
  • Fonseca-Berzal, Cristina
  • Manzano, José Ignacio
  • Kraeutler, Damien
  • Ungogo, Marzuq A.
  • Aloraini, Maha A.
  • Elati, Hamza A. A.
  • Ibáñez-Escribano, Alexandra
  • Lagartera, Laura
  • Herraiz Tomico, Tomás
  • Gamarro, Francisco
  • Koning, Harry P. de
  • Gómez-Barrio, Alicia
  • Dardonville, Christophe
The AT-rich mitochondrial DNA (kDNA) of trypanosomatid parasites is a target of DNA minor groove binders. We report the synthesis, antiprotozoal screening, and SAR studies of three series of analogues of the known antiprotozoal kDNA binder 2-((4-(4-((4,5-dihydro-1H-imidazol-3-ium-2-yl)amino)benzamido)phenyl)amino)-4,5-dihydro-1H-imidazol-3-ium (1a). Bis(2-aminoimidazolines) (1) and bis(2-aminobenzimidazoles) (2) showed micromolar range activity against Trypanosoma brucei, whereas bisarylimidamides (3) were submicromolar inhibitors of T. brucei, Trypanosoma cruzi, and Leishmania donovani. None of the compounds showed relevant activity against the urogenital, nonkinetoplastid parasite Trichomonas vaginalis. We show that series 1 and 3 bind strongly and selectively to the minor groove of AT DNA, whereas series 2 also binds by intercalation. The measured pKa indicated different ionization states at pH 7.4, which correlated with the DNA binding affinities (ΔTm) for series 2 and 3. Compound 3a, which was active and selective against the three parasites and displayed adequate metabolic stability, is a fine candidate for in vivo studies., This study was funded by Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033) through the projects RTI2018–093940–B-I00 (C.D.) and RTI2018–097210–B–I00 (F.G.) (Co-funded by the European Regional Development Fund. ERDF, “A way to build Europe”), and PDC2022–133269-I00 (funded by the Recovery and Resilience Facility, RRF, NextGenerationEU). M.A.U. was funded by a studentship from the Petroleum Technology Development Fund, Abuja, Nigeria. H.A.A.E. is supported by a PhD studentship from the Libyan Government and M.A.A. by a PhD studentship from the Saudi Arabian Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacophore identification and structure-activity relationship analysis of a series of substituted azaindoles as inhibitors of Trypanosoma brucei

  • Ferrins, Lori
  • Díaz, Rosario
  • Cordon-Obras, Carlos
  • Rojas-Barros, Domingo I.
  • Quotadamo, Antonio
  • Oehme, Daniel P.
  • Ceballos-Pérez, Gloria
  • Swaminathan, Uma
  • Pérez-Moreno, Guiomar
  • Bosch-Navarrete, Cristina
  • García-Hernández, Raquel
  • Gómez-Liñán, Claudia
  • Saura, Andreu
  • Ruiz-Pérez, Luis Miguel
  • Gamarro, Francisco
  • Martínez-Martínez, María S.
  • Manzano, Pilar
  • González-Pacanowska, Dolores
  • Navarro, Miguel
  • Pollastri, Michael P.
Human African trypanosomiasis is among the World Health Organization’s designated neglected tropical diseases. Repurposing strategies are often employed in academic drug discovery programs due to financial limitations, and in this instance, we used human kinase inhibitor chemotypes to identify substituted 4-aminoazaindoles, exemplified by 1. Structure–activity and structure–property relationship analysis, informed by cheminformatics, identified 4s as a potent inhibitor of Trypanosoma brucei growth. While 4s appeared to be fast acting and cidal in the in vitro assays, it failed to cure a murine model of infection. Preliminary efforts to identify the potential mechanism of action of the series pointed to arginine kinase, though, as we demonstrate, this does not appear to be the sole target of our compounds. This comprehensive approach to drug discovery, encompassing cheminformatics, structure–potency and structure–property analysis, and pharmacophore identification, highlights our multipronged efforts to identify novel lead compounds for this deadly disease., The authors acknowledge funding from the National Institute of Allergy and Infectious Diseases (M.P.P., M.N., and D.G.-P., R01AI114685; M.P.P., R21AI127594 and R01AI124046), the Spanish Ministerio de Ciencia, Innovación y Universidades, (D.G-P., Grant PID2022-142971OB-I00, funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; M.N., SAF2015-71444), the Subdirección General de Redes y Centros de Investigación Cooperativa (RICET) (M.N., RD16/0027/0019; D.G.-P., RD16/0027/0014), RTI2018-098834-B-I00 (MINCIU-FEDER) to M.N., and RTI2018-097210-B-I00 (MINCIU-FEDER) to F.G., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deciphering host-parasite interplay in Leishmania infection through a one health view of proteomics studies on drug resistance

  • Tagliazucchi, Lorenzo
  • Pinetti, Diego
  • Genovese, Filippo
  • Malpezzi, Giulia
  • Perea Martínez, Ana
  • Manzano, José Ignacio
  • García-Hernández, Raquel
  • Cole, Alexander R.
  • Kwon, Ba Reum
  • Aiello, Daniele
  • Brooks, Bryan W.
  • Thoré, Eli S. J.
  • Bertram, Michael G.
  • Gamarro, Francisco
  • Costi, Maria Paola
Published as part of ACS Infectious Diseases virtual special issue “One Health and Vector Borne Parasitic Diseases”., Recent efforts in the study of vector-borne parasitic diseases (VBPDs) have emphasized an increased consideration for preventing drug resistance and promoting the environmental safety of drugs, from the beginning of the drug discovery pipeline. The intensive use of the few available antileishmanial drugs has led to the spreading of hyper-resistant Leishmania infantum strains, resulting in a chronic burden of the disease. In the present work, we have investigated the biochemical mechanisms of resistance to antimonials, paromomycin, and miltefosine in three drug-resistant parasitic strains from human clinical isolates, using a whole-cell mass spectrometry proteomics approach. We identified 14 differentially expressed proteins that were validated with their transcripts. Next, we employed functional association networks to identify parasite-specific proteins as potential targets for novel drug discovery studies. We used SeqAPASS analysis to predict susceptibility based on the evolutionary conservation of protein drug targets across species. MATH-domain-containing protein, adenosine triphosphate (ATP)-binding cassette B2, histone H4, calpain-like cysteine peptidase, and trypanothione reductase emerged as top candidates. Overall, this work identifies new biological targets for designing drugs to prevent the development of Leishmania drug resistance, while aligning with One Health principles that emphasize the interconnected health of people, animals, and ecosystems., We thank Dr. F. Javier Moreno from the WHO Collaborating Centre for Leishmaniasis, Instituto de Salud Carlos III (ISCIII), for providing L. infantum lines LLM2070, LLM2165, LLM2255, and LLM2221, isolated from HIV-positive patients with visceral leishmaniasis and TF, and the paromomycin-resistant L. infantum line LEM2126 (L2126) used in this study. Also, we thank Dr. Laurence Lachaud from the Centre National de Référence des Leishmanioses, Université Montpellier (Montpellier, France), for providing the drug-resistant L. infantum lines used in this work: LEM3323 (L3323) and LEM5159 (L5159), which are SbIII- and MIL-resistant lines, respectively. The authors acknowledge Dr. Sotiris Ouzounis for critically reading the manuscript and providing suggestions for the statistics part. The authors also thank Dr. Stefania Ferrari for annotating L. infantum database for protein search, which was obtained from SwissProt (L. infantum entry, exported in FASTA format, updated January 2023, updates are ongoing). The authors acknowledge the “Fondazione Cassa di Risparmio di Modena” for funding the UHPLC-ESI-HRMS Q-Exactive system at the Centro Interdipartimentale Grandi Strumenti (CIGS) of the University of Modena and Reggio Emilia., This work was inspired and developed within the COST Action “OneHealthdrugs” CA21111. Thanks are due to Grant RTI2018-097210-B-100 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A Way of Making Europe” awarded to F. Gamarro., Peer reviewed